Ribociclib

BreastfeedingPediatric
  • TRADE NAME: Kisqali (Novartis)
  • INDICATIONS: Treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer (in combination with an aromatase inhibitor)
  • CLASS: Cyclin-dependent kinase (CDK) 4/6 inhibitor
  • HALF-LIFE: 30–55 hours

FDA APPROVAL DATE: 03/13/2017

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alfentanil, Amiodarone, Bepridil, Boceprevir, Chloroquine, Clarithromycin, Conivaptan, Cyclosporine, CYP3A4 substrates, Dihydroergotamine, Disopyramide, Ergotamine, Everolimus, Fentanyl, Grapefruit Juice, Halofantrine, Haloperidol, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Methadone, Midazolam, Moxifloxacin, Ondansetron, Pimozide, Procainamide, QT prolonging drugs, Quinidine, Rifampin, Ritonavir, Saquinavir, Sirolimus, Sotalol, Strong CYP3A4 inducers and inhibitors, Tacrolimus, Voriconazole

PREGNANCY CATEGORY: N/A
Can cause fetal harm

Our database has 38 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 09/25/2022

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top